Puma Biotechnology sells $2.5M of common stock to CEO Alan Auerbach in private placement

PUMA BIOTECHNOLOGY, INC.

Sold 568,181 shares of common stock to CEO Alan Auerbach at $4.40/share, gross proceeds ~$2.5M.
Purchase price equaled December 9, 2022 closing price; private placement closed December 12, 2022.
Shares issued under Section 4(a)(2) exemption, not registered under Securities Act.
Proceeds for general corporate purposes; no specific use disclosed.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

PUMA BIOTECHNOLOGY, INC. entered into Securities Purchase Agreement with Alan H. Auerbach valued at approximately $2.5 million (effective 2022-12-09).

Action: entry
Agreement: equity purchase
Counterparty: Alan H. Auerbach
Value: approximately $2.5 million
Effective: 2022-12-09

Exact text from the filing

On December 9, 2022, Puma Biotechnology, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Alan H. Auerbach, the Company’s President, Chief Executive Officer and Chairman of the Board (the “Purchaser”).

View on SEC.gov

Browse all material agreements →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-22-028937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.